In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 12, 2005, Pages 1343-1348

  Menzies, Dick ^a   Dion, M J ^a   Francis, D ^a   Parisien, I ^a   Rocher, I ^a   Mannix, S ^a   Schwartzman, K ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Adherence; Adherence measurement; Latent TB infection; Preventive treatment; TB prevention

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; CARRIER STATE; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISONIAZID; MALE; PATIENT COMPLIANCE; RIFAMPIN; TUBERCULOSIS;

EID: 33144454455     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247.
2. Long R. Canadian tuberculosis standards. 2000/2001 ed. Toronto, Canada: Canadian Lung Association, 2000.
3. Morisky D E, Malotte C K, Choi P, et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q 1990; 17: 253-267.
4. Cuneo W D, Snider D E Jr. Enhancing patient compliance with tuberculosis therapy. Clinics Chest Med 1989; 10: 375-380.
5. Malotte C K, Hollingshead J R, Larro M. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med 2001; 20: 103-107.
6. Haynes R B, McKibbon K A, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383-386.
7. Chaisson R E, Barnes G L, Hackman J, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 2001; 110: 610-615.
8. Besch C L. Compliance in clinical trials. AIDS 1995; 9: 1-10.
9. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet 1994; 27: 202-215.
10. Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449.
11. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
12. Dawson-Saunders B, Trapp R G. Basic and clinical biostatistics. Norwalk, CT: Appleton Sc Lange, 1990.
13. Gourevitch M N, Alcabes P, Wasserman W C, Arno P S. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 531-540.
14. McNab B D, Marciniuk D D, Alvi R A, Tan L, Hoeppner V H. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian Plains Aborigines. Am J Respir Crit Care Med 2000; 162: 989-993.
15. Moulding T S, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. Int J Tuberc Lung Dis 2002; 6: 313-319.
16. Mason B J, Matsuyama J R, Jue S G. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educator 1995; 21: 52-57.
17. Moulding T. The unrealized potential of the medication monitor. Clin Pharmacol Ther 1979; 25: 131-135.
18. Namkoong K, Farren C K, O'Connor P G, O'Malley S S. Measurement of compliance with naltreone in the treatment of alcohol dependence: research and clinical implications. J Clin Psychiatry 1999; 60: 449-453.
19. Dasgupta K, Schwartzman K, Marchand R, Tannenbaum T N, Brassard P, Menzies D. Comparison of cost effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162: 2079-2086.
20. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.